Ask AI
ProCE Banner Activity

Experts Answer Your Pressing Questions on PARP Inhibitors in Metastatic Prostate Cancer

Clinical Thought

In this commentary, expert faculty answer questions on biomarker testing and the use of PARP inhibitors for metastatic prostate cancer.

Released: April 15, 2026

Share

Provided by

Provided by the National Comprehensive Cancer Network (NCCN) in collaboration with Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca. Supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.

AstraZeneca

Merck & Co., Inc., Rahway, NJ, USA

Partners

Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Target Audience

This activity is intended for community oncologists, urologists, oncology nurses and nurse practitioners, physician assistants, pharmacists, and other healthcare professionals involved in the care and treatment of patients with prostate cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Incorporate genetic testing workflows in concordance with guideline recommendations for all HRR mutations to identify patients who may benefit from PARP inhibitor-based therapy

  • Evaluate efficacy, treatment sequencing, and subgroup data from recent trials of PARPi combinations in mPC, and assess their implications across BRCA and non-BRCA HRR mutation populations

  • Formulate patient care plans with PARP inhibitor-based combination regimens for the treatment of patients with mPC, taking into account recent guideline updates for sequencing, expert recommendations, and recent data, including patient subgroup data

  • Employ multidisciplinary strategies for ongoing therapy management to mitigate and manage adverse events associated with PARPi combination regimens, thereby improving quality of life, adherence, and outcomes in patients with mPC

  • Integrate strategies to identify and address barriers to appropriate genetic and biomarker testing for patients with mPC, including testing workflows and the role of the multidisciplinary care team

Disclosure

Primary Author

Wassim Abida, MD, PhD: consultant/advisor/speaker: Aptitude Health, AstraZeneca, BoundlessBio, Duality, IDEOlogy, Tolmar.

Nabil Adra, MD, MS: consultant/advisor/speaker: Merck.

Neeraj Agarwal, MD, FASCO, has no relevant financial relationships to disclose.

Kristine Peregrino Lacuna, MD: consultant/advisor/speaker: Bayer.